Molecular pathogenesis of follicular cell derived thyroid cancers
Authors:
- Rajeev ParameswaranRPRajeev Parameswaran
- Gregory Paul SadlerGSGregory Paul Sadler
- 1 January 2010
- journal article
- review article
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 8 (3) , 186-193
Abstract
Thyroid cancers are the most common endocrine malignancy. Radiation exposure, family history of thyroid cancer and some inherited conditions are the most important predisposing factors for the development of thyroid cancer. Three mitogenic signalling pathways have been described in the thyroid cell, which are influenced by various stimulatory and inhibitory hormones, growth factors and neurotransmitters. Various proto-oncogenes and oncogenes like ras, braf, trk, met and RET also play a role in the signal transduction systems. Two theories have been described in thyroid cancer pathogenesis, the foetal cell carcinogenesis theory and the more common, multistep carcinogenesis theory. The multistep carcinogenesis theory is now the accepted model in many human cancers, including thyroid cancer. The early events of tumour formation are the consequence of activation of either various growth factors or the proto-oncogenes like ras, met or ret. This results in the formation of differentiated thyroid cancers like the papillary, follicular or Hurthle cell cancers. The later stages of tumour formation involve further activation of proto-oncogenes and loss or inactivation of tumour suppressor genes like p53. Based on this theory, follicular carcinomas are generated from follicular adenomas and papillary carcinomas from precursor cells generated from thyrocytes. Anaplastic carcinoma may develop from papillary or follicular carcinoma by dedifferentiation. In this review article, we highlight the molecular pathogenesis of thyroid tumours.Keywords
This publication has 110 references indexed in Scilit:
- Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced MalignanciesClinical Cancer Research, 2009
- Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutationsBMC Cancer, 2009
- Oncogenic Kras Requires Simultaneous PI3K Signaling to Induce ERK Activation and Transform Thyroid Epithelial Cells In vivoCancer Research, 2009
- Aneuploidy: Instigator and Inhibitor of TumorigenesisCancer Research, 2007
- RET and neuroendocrine tumorsCancer Letters, 2004
- Mutations of the BRAF gene in human cancerNature, 2002
- Mitochondrial DNA Somatic Mutations (Point Mutations and Large Deletions) and Mitochondrial DNA Variants in Human Thyroid PathologyThe American Journal of Pathology, 2002
- Follicular and Hurthle Cell Carcinomas of the ThyroidAmerican Journal of Surgical Pathology, 1998
- DNA aneuploidy in follicular thyroid neoplasiaBritish Journal of Surgery, 1991
- Genetic Alterations during Colorectal-Tumor DevelopmentNew England Journal of Medicine, 1988